Across TCGA pan-cancer cohorts, UBXN2B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of UBXN2B’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where UBXN2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types UBXN2B is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

COAD, LSCC, and CCRCC are the cancer types where UBXN2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBXN2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	−0.863	<.001	8	view →
LSCC	Male	II,III,IV	−0.137	.001	5	view →
CCRCC	Male	II,III,IV	+0.081	.038	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: UBXN2B RNA expression & survival · all UBXN2B data types